All In Biotech

Drug Trial Radar · NCT05027568

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

Randomized, Double-blind, Placebo-controlled, Dose Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of IOA-289 in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jun 28, 2021

Primary completion

Sep 7, 2021

Study completion Sep 7, 2021

Sponsor

Lead sponsor
iOncturaIndustry
Sponsor type
Industry
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability after single ascending oral doses of IOA-289 given to healthy male subjects, compared to placebo. After the oral dose administrations, the amount of IOA-289 present in serum will be determined for pharmacokinetic characterisation. Also the reduction of LPA in plasma will be determined as a pharmacodynamic biomarker. Part 2 is optional and its conduct will be dependent on the pharmacokinetic data generated in Part 1. Part 2 will be a randomized, crossover, open label, single oral dose administration of IOA-289 to healthy male subjects either in a fasted state, or after a high-fat meal.

Conditions

  • Healthy

Interventions

  • IOA-289Drug

    Daily oral twice daily dosing of IOA-289

  • Nab paclitaxel / gemcitabineDrug

    Given in combination with IOA-289

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of participants with treatment-related adverse events as assessed by MedDRA v24Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centro Ricerche Cliniche di Verona srl

    Verona, Verona, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.